Imaging brain changes over time in people with Huntington disease and gene carriers
Uses PET and MRI brain scans to track changes in Huntington disease over time.
Plain-language title generated from the registry record
Registry title: IMarkHD: in Vivo Longitudinal Imaging of HD Pathology
Key facts
- Where
- London, United KingdomSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 21 and 75 years old?
Source: NCT03434548, who can take part
Where in United Kingdom
- King's College LondonLondon, United KingdomTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- King's College London
- Trial code
- NCT03434548
- Record updated
- 5 March 2025
- Original description
iMarkHD is an adaptive, longitudinal positron emission tomography (PET) and magnetic resonance (MR) imaging study in Huntington's disease (HD) that aims to assess abnormal molecular, functional, and structural changes in participants' brains, ranging from several years before symptom onset to the advanced symptom stage. The study will be conducted over a three (3) year period (Baseline, Year-1, and Year-2).Read full original descriptionShow less
Longitudinal Adaptive Study of Molecular Pathology and Neuronal Networks in Huntington's Disease Gene-Expansion Carriers (HDGEC) and Healthy Controls Using Positron Emission Tomography (PET) and Multi-modal Magnetic Resonance Imaging (MRI)
iMarkHD is an adaptive, longitudinal positron emission tomography (PET) and magnetic resonance (MR) imaging study in Huntington's disease (HD) that aims to assess abnormal molecular, functional, and structural changes in participants' brains, ranging from several years before symptom onset to the advanced symptom stage. The study will be conducted over a three (3) year period (Baseline, Year-1, and Year-2).
Inclusion: PwHDs and HC participants:; Female and male adults, aged 21-75 years old, inclusive; Adequate visual (Snellen chart) and auditory (Rinne and Weber tests) acuity to complete the psychological testing as determined by the investigator; Capable of giving informed consent; Willing to comply with highly effective contraceptive measures following informed consent (for Cohort 2 only); Vital signs within certain set ranges; Considered by the investigator to be in good health as judged by the absence of clinically significant diseases, laboratory values, physical examination, and able to travel to imaging and clinical assessment centers in London, UK; Suitable physically and psychologically to travel (with a companion if requested) and undergo the assessments as judged by the investigator; PwHDs without symptoms: (approximately HD-ISS stage 0 or 1); HDGECs with ≥ 40 CAG repeats; TMS ≤ 6 AND TFC ≥ 12 AND CAP > 70 PwHDs with symptoms in early disease: (approximately HD-ISS stage 2); HDGECs with ≥ 40 CAG repeats; If one of the following criteria is met:; TMS ≤ 6 AND TFC = 11; TMS is between 7 and 23 inclusive AND TFC is between 11 and 13 inclusive; TMS is between 24 and 33 inclusive AND SDMT > 50 AND TFC is between 11 and 13 inclusive PwHDs with symptoms in late disease (approximately HD-ISS stage 3); HDGECs with ≥ 40 CAG repeats; If one of the following criteria is met:; TMS ≤ 6 AND TFC is between 7 and 10 inclusive; TMS is between 7 and 23 inclusive AND TFC is between 8 and 10 inclusive; TMS is between 24 and 33 inclusive AND SDMT > 50 AND TFC is between 7 and 10 inclusive; TMS is between 7 and 23 inclusive AND TFC = 7; TMS > 23 AND SDMT ≤ 50 AND TFC is between 7 and 13 inclusive; TMS > 33 AND SDMT > 50 AND TFC is between 7 and 13 inclusive; Healthy Controls (HC):; Age- and sex-matched, and balanced (±8 years) with PwHDs; No known family history of HD or have known family history of HD but have been tested for the huntingtin gene glutamine codon (CAG) expansion and are not at genetic risk for HD (CAG < 36).
Exclusion: Participants using any medications with known actions on cannabinoid type 1 receptors (CB1R), phosphodiesterase 10A (PDE-10A), 5-hydroxytryptamine-2A receptor (5-HT2AR), histamine type-3 receptors (H3R), or any other PET targets used in iMarkHD; History of alcoholism or substance abuse within 3 years prior to study entry; Any concurrent conditions that could interfere with the safety and/or tolerability measurements; Presence or history of other neurological condition (including brain surgery, intracranial hematoma, stroke/cerebrovascular disorders, demyelinating conditions, epilepsy) likely to interfere with imaging or PET studies or abnormal neurologic examination finding suggestive of a central nervous system pathology (for PwHDs - other than HD); Presence or history of primary psychiatric disorders unrelated to HD; Contraindication to MRI, such as presence of metal devices or implants (e.g. pacemaker, vascular- or heart- valves, stents, clips), metal deposited in the body (e.g. bullets or shells), or metal grains in the eyes; Failure of drug screen for substances of abuse such as amphetamines, barbiturates, benzodiazepines, methadone, opiates, cocaine, cannabinoids, phencyclidine, and creatine; History of cancer; Contraindication for arterial cannulation as judged by the Allen test and the laboratory blood screening for coagulopathy (Cohort 2 only); PwHD and HC participants:; Pregnancy confirmed by a positive urine pregnancy test; Participants who are currently breastfeeding or intend to breastfeed during the study; Claustrophobia; Significant back pain that makes prolonged laying on the PET or MRI scanner intolerable; Inability to communicate or cooperate with the principal investigator/iMarkHD team for any reason; Participants who are currently enrolled in or participated in clinical trials testing the efficacy of novel therapeutics with action on the specific PET targets being tested within 3 months of screening.